Background: Relatively little is known regarding the association between objective measures of physical function such as cardiorespiratory fitness (CRF) and cognitive function tests in healthy older adults. Objective: To evaluate the relationship between CRF and cognitive function in adults aged 55 and older. Methods: Between 2008 and 2017, 4,931 men and women underwent a comprehensive preventive physical exam at the Cooper Clinic in Dallas, Texas. CRF was determined by duration of a maximal treadmill exercise test. Cognitive function was evaluated with the Montreal Cognitive Assessment (MoCA). In a multivariate model, adjusted odds ratios with 95% confidence intervals for MoCA scores < 26 (i.e., cognitive impairment) were determined by using CRF as both a continuous and a categorical variable. Results: The mean age of the sample was 61.0 ± 6.0 years; mean maximal MET values were 10.0 ± 2.2. Mean MoCA scores were 26.9 ± 2.2; 23.4% of the sample had MoCA scores indicative of cognitive impairment. The odds ratio for cognitive impairment was 0.93 (0.88–0.97) per 1-MET increment in CRF. When examined as a categorical variable, and using the lowest CRF quintile as the referent, there was a significantly reduced likelihood for cognitive impairment across the remaining ordered CRF categories (p trend = 0.004). Conclusion: The association between CRF and MoCA score in older adults suggests that meeting or exceeding public health guidelines for physical activity is likely to increase CRF in low fit individuals, maintain CRF in those with a moderate to high level of CRF, and thereby help to maintain cognitive function in healthy older adults.

Keywords:
Cardiorespiratory fitness, Montreal cognitive assessment, Cognitive impairment
1.
Centers for Disease Control and Prevention: Trends in aging – United States and worldwide. MMWR Morb Mortal Wkly Rep 2003; 52: 101–104, 106.
2.
Rocca WA, et al: Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011; 7: 80–93.
3.
Alzheimer’s Association: 2012 Alzheimer’s disease facts and figures. Alzheimers Dement 2012; 8: 131–168.
4.
Daviglus ML, et al: NIH state-of-the-science conference statement: preventing Alzheimer’s disease and cognitive decline. NIH Consens State Sci Statements 2010; 27: 1–30.
5.
Laurin D, et al: Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001; 58: 498–504.
6.
Hamer M, Chida Y: Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009; 39: 3–11.
7.
Myers J, et al: Fitness versus physical activity patterns in predicting mortality in men. Am J Med 2004; 117: 912–918.
8.
Williams PT: Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc 2001; 33: 754–761.
9.
Blair SN, et al: Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262: 2395–2401.
10.
Farrell SW, et al: Cardiorespiratory fitness, different measures of adiposity, and total cancer mortality in women. Obesity (Silver Spring) 2011; 19: 2261–2267.
11.
LaMonte MJ, et al: Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation 2005; 112: 505–512.
12.
Kodama S, et al: Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009; 301: 2024–2035.
13.
Gulati M, et al: Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation 2003; 108: 1554–1559.
14.
Hayes SM, Forman DE, Verfaellie M: Cardiorespiratory fitness is associated with cognitive performance in older but not younger adults. J Gerontol B Psychol Sci Soc Sci 2016; 71: 474–482.
15.
Edwards MK, Loprinzi PD: Combined associations of sedentary behavior and cardiorespiratory fitness on cognitive function among older adults. Int J Cardiol 2017; 229: 71–74.
16.
Nasreddine ZS, et al: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.
17.
Pollock ML, et al: A comparative analysis of four protocols for maximal treadmill stress testing. Am Heart J 1976; 92: 39–46.
18.
Pollock ML, et al: Comparative analysis of physiologic responses to three different maximal graded exercise test protocols in healthy women. Am Heart J 1982; 103: 363–373.
19.
American College of Sports Medicine: ACSM’s Guidelines for Exercise Testing and Prescription. Philadelphia, Lippincott Williams & Wilkins, 2013.
20.
Muller J, Chan K, Myers JN: Association between exercise capacity and late onset of dementia, Alzheimer disease, and cognitive impairment. Mayo Clin Proc 2017; 92: 211–217.
21.
Defina LF, et al: The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study. Ann Intern Med 2013; 158: 162–168.
22.
Haskell WL, et al: Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007; 39: 1423–1434.
23.
Baker LD, et al: Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010; 67: 71–79.
24.
Berryman N, et al: Multiple roads lead to Rome: combined high-intensity aerobic and strength training vs gross motor activities leads to equivalent improvement in executive functions in a cohort of healthy older adults. Age (Dordr) 2014; 36: 9710.
25.
Suzuki T, et al: Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment: a randomized controlled trial. BMC Neurol 2012; 12: 128.
26.
Smith PJ, et al: Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med 2010; 72: 239–252.
27.
Baker LD, et al: Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer’s disease. J Alzheimers Dis 2010; 22: 569–579.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.